NASDAQ:BTAI BioXcel Therapeutics (BTAI) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free BTAI Stock Alerts $2.82 -0.06 (-2.08%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.79▼$2.9150-Day Range$1.95▼$4.0452-Week Range$1.91▼$29.56Volume335,500 shsAverage Volume685,548 shsMarket Capitalization$86.24 millionP/E RatioN/ADividend YieldN/APrice Target$16.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get BioXcel Therapeutics alerts: Email Address BioXcel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside497.8% Upside$16.86 Price TargetShort InterestHealthy14.63% of Float Sold ShortDividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews Sentiment0.69Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.28) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.34 out of 5 starsMedical Sector129th out of 938 stocksPharmaceutical Preparations Industry54th out of 432 stocks 3.2 Analyst's Opinion Consensus RatingBioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.86, BioXcel Therapeutics has a forecasted upside of 497.8% from its current price of $2.82.Amount of Analyst CoverageBioXcel Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted14.63% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioXcel Therapeutics has recently decreased by 20.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for BioXcel Therapeutics is -1.13. Previous Next 2.6 News and Social Media Coverage News SentimentBioXcel Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BioXcel Therapeutics this week, compared to 5 articles on an average week.Search Interest24 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.MarketBeat Follows11 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.80% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.68% of the stock of BioXcel Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($2.28) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioXcel Therapeutics has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About BioXcel Therapeutics Stock (NASDAQ:BTAI)BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.Read More BTAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTAI Stock News HeadlinesMarch 25, 2024 | globenewswire.comBioXcel Therapeutics Announces $25 Million Registered Direct OfferingMarch 25, 2024 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Average Rating of "Hold" by AnalystsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 24, 2024 | finance.yahoo.comBioXcel Therapeutics Full Year 2023 Earnings: Revenues DisappointMarch 20, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for BioXcel Therapeutics, Inc. Lifted by Analyst (NASDAQ:BTAI)March 19, 2024 | americanbankingnews.comBioXcel Therapeutics (NASDAQ:BTAI) Given "Buy" Rating at HC WainwrightMarch 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 ExpansionMarch 15, 2024 | au.news.yahoo.comTapeworm eggs found in brain of man with penchant for 'undercooked' baconMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 15, 2024 | markets.businessinsider.comBioXcel Gets European Patent For Sublingual Dexmedetomidine To Treat Agitation In Dementia PatientsMarch 15, 2024 | markets.businessinsider.comBioxcel Therapeutics: Hold Rating Amid Financial and Operational UncertaintiesMarch 15, 2024 | tmcnet.comBioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineMarch 15, 2024 | finance.yahoo.comBioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineMarch 15, 2024 | globenewswire.comBioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineMarch 15, 2024 | msn.comFDA approves first drug for serious liver diseaseMarch 15, 2024 | msn.comPetco CEO Ron Coughlin steps down, ex-BestBuy exec named as replacementMarch 15, 2024 | au.lifestyle.yahoo.comApple acquires AI startup specializing in overlooking manufacturing componentsMarch 15, 2024 | msn.comInfectious disease outbreak at major festivalMarch 14, 2024 | au.news.yahoo.comTwo words health boss wants scrappedMarch 14, 2024 | au.news.yahoo.comSeven tips on how to lower your blood pressure, according to Doctor Hilary JonesMarch 14, 2024 | seekingalpha.comBioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | msn.comCovid patients wrongly issued with ‘do not resuscitate’ orders, watchdog findsMarch 14, 2024 | msn.comAs Hershey battles cocoa costs, chocolate lovers may help cool inflationMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioXcel Therapeutics Amid Label Expansion and Strong Clinical ProspectsMarch 13, 2024 | finance.yahoo.comQ4 2023 BioXcel Therapeutics Inc Earnings CallMarch 12, 2024 | markets.businessinsider.comHere's what Wall Street expects from BioXcel Therapeutics's earningsMarch 12, 2024 | globenewswire.comBioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023See More Headlines Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BTAI CUSIPN/A CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees183Year Founded2017Price Target and Rating Average Stock Price Target$16.86 High Stock Price Target$40.00 Low Stock Price Target$4.00 Potential Upside/Downside+497.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($6.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,050,000.00 Net Margins-12,974.86% Pretax Margin-12,974.86% Return on Equity-2,941.56% Return on Assets-144.88% Debt Debt-to-Equity Ratio16.52 Current Ratio2.65 Quick Ratio2.45 Sales & Book Value Annual Sales$1.38 million Price / Sales62.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book1.03Miscellaneous Outstanding Shares30,580,000Free Float19,630,000Market Cap$86.24 million OptionableOptionable Beta0.42 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Vimal D. Mehta Ph.D. (Age 62)Founder, CEO, President, & Director Comp: $1.76MMr. Javier Rodriguez (Age 51)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $638.88kMr. Matthew Wiley (Age 51)Senior VP & Chief Commercial Officer Comp: $620.12kMr. Richard I. Steinhart MBA (Age 67)Senior VP & CFO Comp: $404kDr. Frank D. Yocca Ph.D. (Age 67)Senior VP & Chief Scientific Officer Comp: $452.58kDr. Vincent J. O'Neill B.Sc. (Age 55)M.D., M.R.C.P., Executive VP, Chief of Product Development & Medical Officer Comp: $510.17kDr. Chetan D. Lathia Ph.D.Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory AffairsDr. Robert Risinger M.D.Chief Medical Officer - NeuroscienceMr. Robert Scala (Age 55)Vice President of Commercial Operations & Launch Planning Dr. Friso PostmaSenior Director of Neuroscience & Artificial intelligenceMore ExecutivesKey CompetitorsChimerixNASDAQ:CMRXPMV PharmaceuticalsNASDAQ:PMVPRezoluteNASDAQ:RZLTVeruNASDAQ:VERUAclaris TherapeuticsNASDAQ:ACRSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 131,067 shares on 3/11/2024Ownership: 3.586%Goldman Sachs Group Inc.Sold 113,674 shares on 3/1/2024Ownership: 0.063%Virtu Financial LLCBought 59,514 shares on 2/26/2024Ownership: 0.196%Citadel Advisors LLCSold 18,100 shares on 2/15/2024Ownership: 0.000%Barclays PLCBought 20,239 shares on 2/15/2024Ownership: 0.092%View All Insider TransactionsView All Institutional Transactions BTAI Stock Analysis - Frequently Asked Questions Should I buy or sell BioXcel Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares. View BTAI analyst ratings or view top-rated stocks. What is BioXcel Therapeutics' stock price target for 2024? 7 equities research analysts have issued 12 month price objectives for BioXcel Therapeutics' stock. Their BTAI share price targets range from $4.00 to $40.00. On average, they expect the company's share price to reach $16.86 in the next twelve months. This suggests a possible upside of 497.8% from the stock's current price. View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts. How have BTAI shares performed in 2024? BioXcel Therapeutics' stock was trading at $2.95 at the start of the year. Since then, BTAI shares have decreased by 4.4% and is now trading at $2.82. View the best growth stocks for 2024 here. Are investors shorting BioXcel Therapeutics? BioXcel Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 3,140,000 shares, a drop of 20.9% from the February 29th total of 3,970,000 shares. Based on an average trading volume of 1,530,000 shares, the short-interest ratio is currently 2.1 days. Approximately 14.6% of the company's shares are sold short. View BioXcel Therapeutics' Short Interest. When is BioXcel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our BTAI earnings forecast. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings data on Monday, August, 14th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The company earned $0.46 million during the quarter, compared to analysts' expectations of $0.42 million. BioXcel Therapeutics had a negative trailing twelve-month return on equity of 2,941.56% and a negative net margin of 12,974.86%. The company's quarterly revenue was up 45600.0% on a year-over-year basis. During the same period in the previous year, the company earned ($1.35) EPS. What ETF holds BioXcel Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT). When did BioXcel Therapeutics IPO? BioXcel Therapeutics (BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are BioXcel Therapeutics' major shareholders? BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.59%), Vanguard Group Inc. (3.59%), Charles Schwab Investment Management Inc. (0.63%), Citadel Advisors LLC (0.00%), Pennant Investors LP (0.28%) and Virtu Financial LLC (0.20%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart and Vimal Mehta. View institutional ownership trends. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTAI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.